Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Analysis of Treatment Patterns and Clinical Outcomes After First-Line Treatment With Tislelizumab in Advanced NSCLC: A Real-World Observational Study

NCT06962449 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT06962449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06962449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Analysis of Treatment Patterns and Clinical Outcomes After First-Line Treatment With Tislelizumab in Advanced NSCLC: A Real-World Observational Study
Lead sponsor
Shanghai Chest Hospital
Phase
Observational
Overall status
Enrolling by invitation
Start date
August 16, 2024
Completion date
December 31, 2026
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer, non-small-cell lung cancer stage iv